Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients.
Aspirin
Cancer
Mortality
NHANES
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
26
02
2024
accepted:
07
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The long-term use of aspirin for preventing cardiovascular disease has been recommended for decades. However, there is currently uncertainty regarding the long-term effects of aspirin use on the risk of all-cause, cardiovascular, and cancer mortality in cancer patients. The aim of this work was to analyze the connection between the prophylactic use of low-dose aspirin and the risk of all-cause death, cardiovascular death, and carcinoma death in carcinoma patients in the United States. A cohort study was conducted using National Health and Nutrition Examination Survey (NHANES) data (2011-2012, 2013-2014, 2015-2016, and 2017-2018) and associated mortality data. The 95% confidence intervals (CIs) and hazard ratios (HRs) between non-aspirin use and prophylactic low-dose aspirin use and the risk of death were measured via Cox proportional hazard regression models. A total of 1819 participants were included in the present research, of whom 945 were nonaspirin users and 874 were prophylactic aspirin users. Compared with non-aspirin users, prophylactic low-dose aspirin users had a decreased risk of all-cause death (HR = 0.647, 95% CI = 0.489-0.857). There was no statistically significant difference in the risk of cardiovascular death (HR = 0.623, 95% CI = 0.362-1.074) or cancer death (HR = 0.709, 95% CI = 0.410-1.226). Prophylactic use of low-dose aspirin may lower all-cause mortality in individuals with cancer but does not have a substantial effect on cardiovascular risk or cancer-specific mortality in this patient population.
Identifiants
pubmed: 39472644
doi: 10.1038/s41598-024-75612-w
pii: 10.1038/s41598-024-75612-w
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25918Subventions
Organisme : National Natural Science Foundation of China
ID : 81960425
Informations de copyright
© 2024. The Author(s).
Références
Cao, W., Chen, H. D., Yu, Y. W., Li, N. & Chen, W. Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134 (7), 783–791. https://doi.org/10.1097/cm9.0000000000001474 (2021).
doi: 10.1097/cm9.0000000000001474
pubmed: 33734139
Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 5 (12), 1749–1768. https://doi.org/10.1001/jamaoncol.2019.2996 (2019).
doi: 10.1001/jamaoncol.2019.2996
pubmed: 31560378
pmcid: 6777271
Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74 (1), 12–49. https://doi.org/10.3322/caac.21820 (2024).
doi: 10.3322/caac.21820
pubmed: 38230766
Hall, D. C. N. & Benndorf, R. A. Aspirin sensitivity of PIK3CA-mutated colorectal cancer: Potential mechanisms revisited. Cell. Mol. Life Sci. 79 (7), 393. https://doi.org/10.1007/s00018-022-04430-y (2022).
doi: 10.1007/s00018-022-04430-y
pubmed: 35780223
pmcid: 9250486
Ornelas, A. et al. Beyond COX-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 36 (2), 289–303. https://doi.org/10.1007/s10555-017-9675-z (2017).
doi: 10.1007/s10555-017-9675-z
pubmed: 28762014
pmcid: 5557878
Chen, Y. et al. Low- or high-dose preventive aspirin use and risk of death from all-cause, cardiovascular disease, and cancer: A nationally representative cohort study. Front. Pharmacol. 14, 1099810. https://doi.org/10.3389/fphar.2023.1099810 (2023).
doi: 10.3389/fphar.2023.1099810
pubmed: 36874020
pmcid: 9974638
Hybiak, J. et al. Aspirin and its pleiotropic application. Eur. J. Pharmacol. 866, 172762. https://doi.org/10.1016/j.ejphar.2019.172762 (2020).
doi: 10.1016/j.ejphar.2019.172762
pubmed: 31669590
Elwood, P. et al. Aspirin and cancer: Biological mechanisms and clinical outcomes. Open. Biol. 12 (9), 220124. https://doi.org/10.1098/rsob.220124 (2022).
doi: 10.1098/rsob.220124
pubmed: 36099932
pmcid: 9470249
Shahrivar, M. et al. Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study. Cancer Med. 12 (1), 315–324. https://doi.org/10.1002/cam4.4859 (2023).
doi: 10.1002/cam4.4859
pubmed: 35717628
Sperling, C. D. et al. Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study. Int. J. Epidemiol. 49 (1), 330–337. https://doi.org/10.1093/ije/dyz253 (2020).
doi: 10.1093/ije/dyz253
pubmed: 31845990
Sturgeon, K. M. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur. Heart J. 40 (48), 3889–3897. https://doi.org/10.1093/eurheartj/ehz766 (2019).
doi: 10.1093/eurheartj/ehz766
pubmed: 31761945
pmcid: 6925383
Yang, B. & Shi, J. Developing new cancer nanomedicines by repurposing old drugs. Angew Chem. Int. Ed. Engl. 59 (49), 21829–21838. https://doi.org/10.1002/anie.202004317 (2020).
doi: 10.1002/anie.202004317
pubmed: 32270570
Patrono, C. & Baigent, C. Role of aspirin in primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 16 (11), 675–686. https://doi.org/10.1038/s41569-019-0225-y (2019).
doi: 10.1038/s41569-019-0225-y
pubmed: 31243390
Downer, M. K. et al. Regular aspirin use and the risk of lethal prostate cancer in the physicians’ health study. Eur. Urol. 72 (5), 821–827. https://doi.org/10.1016/j.eururo.2017.01.044 (2017).
doi: 10.1016/j.eururo.2017.01.044
pubmed: 28189429
Chubak, J. et al. Aspirin for the prevention of cancer incidence and mortality: Systematic evidence reviews for the U.S. preventive services task force. Ann. Intern. Med. 164 (12), 814–825. https://doi.org/10.7326/m15-2117 (2016).
doi: 10.7326/m15-2117
pubmed: 27064482
Elwood, P. C. et al. Aspirin and cancer survival: A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience 15, 1258. https://doi.org/10.3332/ecancer.2021.1258 (2021).
doi: 10.3332/ecancer.2021.1258
pubmed: 34567243
pmcid: 8426031
Liu, J., Zheng, F., Yang, M., Wu, X. & Liu, A. Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. Med. (Baltim) 100 (33), e26870. https://doi.org/10.1097/md.0000000000026870 (2021).
doi: 10.1097/md.0000000000026870
Bowman, L. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl. J. Med. 379 (16), 1529–1539. https://doi.org/10.1056/NEJMoa1804988 (2018).
doi: 10.1056/NEJMoa1804988
pubmed: 30146931
Guirguis-Blake, J. M., Evans, C. V., Perdue, L. A., Bean, S. I. & Senger, C. A. Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US preventive services task force. Jama 327 (16), 1585–1597. https://doi.org/10.1001/jama.2022.3337 (2022).
doi: 10.1001/jama.2022.3337
pubmed: 35471507
McNeil, J. J. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl. J. Med. 379 (16), 1519–1528. https://doi.org/10.1056/NEJMoa1803955 (2018).
doi: 10.1056/NEJMoa1803955
pubmed: 30221595
pmcid: 6433466
Brotons, C., Benamouzig, R., Filipiak, K. J., Limmroth, V. & Borghi, C. A systematic review of aspirin in primary prevention: Is it time for a new approach? Am. J. Cardiovasc. Drugs 15 (2), 113–133. https://doi.org/10.1007/s40256-014-0100-5 (2015).
doi: 10.1007/s40256-014-0100-5
Khan, M. N. & Lee, Y. S. Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. Med. Res. Rev. 31 (2), 161–201. https://doi.org/10.1002/med.20182 (2011).
doi: 10.1002/med.20182
pubmed: 19967720
He, Y. et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncol. Rep. 37 (2), 953–960. https://doi.org/10.3892/or.2017.5353 (2017).
doi: 10.3892/or.2017.5353
pubmed: 28075470
Huang, Y. et al. Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Mol. Cancer Ther. 15 (12), 2894–2904. https://doi.org/10.1158/1535-7163.Mct-16-0074 (2016).
doi: 10.1158/1535-7163.Mct-16-0074
pubmed: 27638860
pmcid: 5136300
Dai, X. et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin. Cancer Res. 23 (20), 6267–6278. https://doi.org/10.1158/1078-0432.Ccr-17-0242 (2017).
doi: 10.1158/1078-0432.Ccr-17-0242
pubmed: 28710312
Elwood, P. C. et al. Aspirin in the treatment of cancer: Reductions in metastatic spread and in mortality: A systematic review and meta-analyses of published studies. PLoS One 11 (4), e0152402. https://doi.org/10.1371/journal.pone.0152402 (2016).
doi: 10.1371/journal.pone.0152402
pubmed: 27096951
pmcid: 4838306